Policymakers are discussing a misguided drug pricing plan—known as “Most Favored Nation” price setting —that would tie the cost of medicines in the U.S. to prices that other countries pay. It sounds like a quick fix, but it actually won’t guarantee lower out-of-pocket costs for patients—and it comes with serious risks.

The policy would:

• Do nothing to rein in insurers and PBMs—who decide what medicines patients can access and what they pay.
• Ignore the real cost drivers—middlemen like PBMs and 340B hospital markups that inflate drug prices and foreign countries that don’t pay their fair share to support global R&D.
• Weakens our economy, ceding our global leadership to China.
• Jeopardize future cures by siphoning billions in R&D—money that could go toward medical breakthroughs and U.S. manufacturing.

Instead of importing foreign price controls, policymakers should focus on real solutions that help patients now—like reining in PBMs, holding 340B hospitals accountable and ending foreign free-riding. Other countries should pay their fair share for innovative medicines and if PBMs and hospitals get lower prices, those savings should go to patients–not profit margins.

Take Action Now

Tell your Representative: Reject Most Favored Nation drug price-setting. Say no to foreign reference pricing that harms patients and threatens biopharmaceutical innovation. Instead, support real solutions that put Americans first.